“If this blog helped you out, don’t keep it to yourself—share the link on your socials!” 👍 “Like what you read? Spread the love and share this blog on your social media.” 👍 “Found this useful? Hit share and let your friends know too!” 👍 “If you enjoyed this post, please share the URL with your friends online.” 👍 “Sharing is caring—drop this link on your social media if it helped you.”

Saturday, August 30, 2025

Apricus Biosciences


Apricus Biosciences products

Vitaros (alprostadil topical cream)
Indication: Erectile dysfunction
Status: Approved and launched in Europe and Canada; Apricus retained U.S. rights but faced FDA rejections and CMC/safety challenges; ex-U.S. rights sold to partners

RayVa (PGE₁ cream)
Indication: Raynaud’s phenomenon (circulatory disorder affecting hands/feet)
Status: Completed Phase 2a clinical trial

Femprox (PGE₁ cream)
Indication: Female sexual interest/arousal disorder
Status: Development candidate (proof-of-concept explored)

NexACT technology
Description: Proprietary permeation enhancer enabling rapid transdermal absorption of active compounds like prostaglandin E₁ for topical delivery
Applications: Core to Vitaros, RayVa, Femprox formulations



on

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)